Biotech Companies Patents Invalid After Crispr Ruling

Biotech Companies Patents Invalid After Crispr Ruling

On Monday, the U.S. Patent and Trademark Office said that the first person to invent the CRISPRCas9 technology for their use in the animal cell was the Broad Institute, siding against the two Nobel Laureates. The Monday ruling on the long-running dispute jeopardizes licensing agreements of a few biotech companies.

More on the story As per Bloomberg News, the ruling on Monday determined that the Nobel winners Emmanuelle Charpentier from the University of Vienna and Jennifer Doudna from the University of California at Berkeley had failed to provide evidence that the two were the first to use in animal cells, their geneediting technology.

The patent battle went on for years. The University of Vienna and the University of California, Berkley had contended that their scientists were the first to find a solution to guide Crispr-Cas9 to

specific locations on the genome. The broad Institute maintained that their scientists first proved that their technology worked in animals, humans, and plants.

Several biotechnology companies, including Crispr Therapeutics AG and Intellia Therapeutics Inc., had licensed the Crispr-Cas9 technology from the University of Vienna, also known as CVC and UC Berkeley.

You can read the full content: https://businessupside.com/2022/03/01/biotech-companies-patentsinvalid-after-crispr-ruling/ -------------------------Business Upside Email ID: support@businessupside.com Phone No.: +1-425-605-0775 Visit Us: https://www.businessupside.com/ Stay Connected Via: https://www.facebook.com/businessupside https://www.youtube.com/channel/UCuSkeS5oUB2tRIBDYntmaw https://twitter.com/BusinessUpside1